Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.

Can-Fite BioPharma (CANF) announced that its lead drug candidate Namodenoson was granted a patent for its use as an anti-obesity drug by the US ...

StockNews.com assumed coverage on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research report report published on Sunday morning. The brokerage issued a sell rating on the stock.

The Namodenoson oral drug is well positioned in the field of anti-obesity agents due to its activity and favorable safety profile Ramat Gan, ...